Release Date: 2024-06-19

Lung Infections in Cystic Fibrosis

Suat Savas (Author), Velat Sen (Author)

Release Date: 2024-06-19

Idiopathic pulmonary fibrosis is a relatively rare disease, with prevalence estimates varying globally. In the United States, prevalence is estimated to be around 14-43 cases per 100,000 people, with higher rates in older populations. The annual incidence is estimated to be 6-16 cases per 100,000 people. There is considerable variation across different countries and regions, [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inPediatric Chest Infection
    First Page113
    Last Page130
    DOIhttps://doi.org/10.69860/nobel.9786053359463.12
    Page Count18
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Idiopathic pulmonary fibrosis is a relatively rare disease, with prevalence estimates varying globally. In the United States, prevalence is estimated to be around 14-43 cases per 100,000 people, with higher rates in older populations. The annual incidence is estimated to be 6-16 cases per 100,000 people. There is considerable variation across different countries and regions, likely due to differences in diagnostic criteria and reporting practices. Idiopathic pulmonary fibrosis primarily affects individuals over 50 years old. The risk increases with age, and it is most commonly diagnosed in people in their 60s and 70s. There is a slight male predominance, with men being affected more frequently than women.

    Suat Savas (Author)
    Necmettin Erbakan University
    https://orcid.org/0000-0002-2733-7194
    3Researcher of Pediatric Pulmonology Dr. Suat Savaş was born in 1990. He received his high school education at Diyarbakır Cumhuriyet Science High School. He completed his medical school education at Mersin University Faculty of Medicine between 2008-2015. He completed his medical specialty training in the field of Pediatrics at Dicle University Faculty of Medicine between 2017-2021. He wrote her specialty thesis on ""Investigation of clinical laboratory and demographic characteristics of patients followed up in our Dicle University Cystic Fibrosis Centre between 2010-2020"". Since 2023, he has been working as a research assistant in Necmettin Erbakan University Faculty of Medicine, Department of Paediatric Chest Diseases. He is a member of the Turkish Thoracic Society, Lung Health and Intensive Care Association, Turkish Paediatric Society and the European Respiratory Society.

    Velat Sen (Author)
    Professor, Dicle University
    https://orcid.org/0000-0002-9232-5982
    3Dr Velat Şen is a professor at Dicle University Faculty of Medicine, Department of Pediatric Chest Diseases. He completed his undergraduate education at Uludağ University Faculty of Medicine and his master’s degree in Paediatrics at Dicle University Faculty of Medicine. In 2012, he started to work as a faculty member in Dicle University Paediatric Chest Diseases. In 2013, he took part in flexible bronchoscopy training in Marmara University Faculty of Medicine, Pediatric Chest Diseases. Dr Şen has supervised more than 10 master theses. His work has led to the publication of more than 100 national and international research articles, oral and poster presentations and reviews.. Since 2021, he has been the founding president of the Eastern Paediatric Association and the president of the Diyarbakır branch of the Turkish Paediatric Association. He is also a member of National Paediatric Association, Turkish Thoracic Society, European Respiratory Society, Lung Health and Intensive Care Association, Pediatric Chest Diseases Association. He is currently the head of the Department of Paediatric Chest Diseases at Dicle University Faculty of Medicine.

    • Shteinberg, M.; Haq, I.J.; Polineni, D.; Davies, J.C. Cystic fibrosis. Lancet 2021, 397, 2195–2211. [Cross- Ref] [PubMed].

    • Nichols, D.P.; Chmiel, J.F. Inflammation and its genesis in cystic fibrosis. Pediatr. Pulmonol. 2015, 50 (Suppl. 40), 39–56. [CrossRef] [PubMed].

    • Nichols, D.; Chmiel, J.; Berger, M. Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling. Clin. Rev. Allergy Immunol. 2008, 34, 146–162. [CrossRef] [PubMed].

    • Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947 2003. Eur Respir J 2007; 29: 522-6.

    • Jackson, L.; Waters, V. Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic f ibrosis. J. Cyst. Fibros. 2021, 20, 8–16. [CrossRef] [PubMed].

    • Chalmers JD, Moffitt Kl, Suarez-cuartin G, Sibila o, Finch S, Furrie E, et al. Neutrophil Elastase Activity ıs Associated with Exacer bations and lung Function Decline in Bronchiectasis. Am J Respir crit care Med. 2017;195(10):1384-93.

    • Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros 2017; 16: 395- 400.

    • Cohen Ts, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med. 2012;18(04):509- 519.

    • Konstan MW, Morgan WJ, Butler sM, Pasta D, Craib MR, silva sJ, et al. scientific Advi sory Group and the Investigators and Coor dinators of the Epidemiologic study of Cysrtic Fibrosis. Risk factors for rate of de cline in forced expiratory volume in one sec ond in children and adolescent with cystic fibrosis. J Pediatr. 2007;151(2):1349.

    • scheithauer s, Haase G, Häusler M, Lemmen s, Ritter K, Kleines M. Association between respiratory and herpes viruses on pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros. 2010;9(03):234-6.

    • Cystic Fibrosis Foundation. Patient Registry 2020 Annual Data Report. Accessed December 17th, 2021. https://www.cff.org/sites/default/files/2021-11/Patient Registry-Annual-Data-Report.pdf .

    • Goss CH, Muhlebach Ms. staphylococcus au reus and MRsA in cystic fibrosis. J. Cyst Fibros. 2011;10:298-306.

    • European Cystic Fibrosis society Patient Reg istry Annual data Report. 2018.

    • Hurley Matthew N, smyth Alan R. staphylococcus Aureus in cystic fibrosis: pivotal role or bit part actor? Curropin Pulm Med. 2018;24(6):586-91.

    • Dasenbrook EC, William C, Christian AM, et al. Association between Respiratory Tract Me thicillin- Resistant staphylococcus Aureus and survival in Cystic Fibrosis, JAMA - Journal of the American Medical Association. 2010; 303: 2386-93.

    • Reynolds D, Kollef M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs 2021; 81:2117–31.

    • Kidd TJ, Canton R, Ekkelenkamp M, Jo hansen H, et al. Antimicrobial resistance in cystic fibrosis international working group. Defining antimincrobial resistance in cystic fibrosis. J Cyst Fibros. 2018;17 (06):696-704.

    • Mayer-Hamblett N, Ramsey BW, Kulasekara HD, Armbruster C, Burns J, Bogart G, et al. Pseudomonas aeruginosa phenotypes asso ciated with eradication failure in children with cystic fibrosis.

    • Treggiari MM, Retsch-Bogart G, Mayer-Ham blett N, Khan U, Kulich M, Kronmal R, et al. Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165:847-56.

    • Ratjen F, Munck A, Kho P, Angyalosi G, Group ES. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286–91.

    • Beaudoin T, Lafayette S, Nguyen D, Rousseau S. Mucoid Pseudomonas aeruginosa caused by mucA mutations result in activation of TLR2 in addition to TLR5 in airway epithelial cells. Biochem Biophys Res Commun 2012; 428:150–4.

    • Baldwin A, Mahenthiralingam E, Drevinek P, Pope C, Waine DJ, Henry DA, et al. Elucidat ing global epidemiology of Burkholderia multi vorans in cases of cystic fibrosis by multilocus sequence typing. J Clin Microbiol 2008;46(01):290-5.

    • Turcios Nl. cystic Fibrosis lung Disease: An overview. Respir care. 2020;65(2):233-51.

    • Zemanick ET, Hoffman lR. cystic Fibrosis: Mi crobiology and Host Response. Pediatr clin North Am. 2016;63(4):617-36.

    • Courtney JM, Dunbar KE, McDowell A, Moore JE, Warke TJ, Stevenson M, et al. clinical out come of Burkholderia cepacia complex infection in cystic fibrosis adults. J cyst Fibros. 2004; 3(2):93-8.

    • Avison MB, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR. Plasmid lo cation and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45:413–9.

    • Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 2000; 44:287–93.

    • Stanojevic S, Ratjen F, Stephens D, lu A, Yau Y, Tullis E, et al. Factors influencing the acqui sition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J cyst Fibros. 2013; 12(6):575-83.

    • Spilker T, Vandamme P, Lipuma JJ. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros May 2013; 12:298–301.

    • lambiase A, catania MR, Del Pezzo M, Rossano F, Terlizzi v, Sepe A, et al. Achro mobacter xylosoxidans respiratory tract infec tion in cystic fibrosis patients. Eur J clin Microbiol ınfect Dis. 2011;30(8):973-80.

    • Blanchard Ac, Waters vJ. Microbiology of cystic Fibrosis Airway Disease. Semin Respir crit care Med. 2019;40(6):727-36.

    • Versalovic J. Manual of Clinical Microbiology, 10th ed. American Society of Microbiology; 2011.

    • Mandell GL, Bennett J, Dolin R. Principles and Practice of Infectious Diseases. Seventh ed. vol 1. Elsevier Churchill Livingstone; 2015.

    • Muhlebach Ms, Hatch JE, Einarsson GG, McGrath sJ, Gilipin DF, Lavelle G, et al. Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study. Eur Respir J. 2018;52(01): 52.

    • Blanchard AC, Waters VJ. Opportunistic Pathogens in Cystic Fibrosis: Epidemiology and Pathogenesis of Lung Infection. J Pediatr Infect Dis Soc. 07 Eylül 2022;11(Supplement_2):S3-12.

    • Olivier KN, Weber DJ, Wallace RJ, Faiz AR, Lee J, zhang Y, et al. Nontuberculous my cobacteria. I: Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:828-34.

    • Martiniano Sl, Nick JA, Daley cl. Nontubercu lous Mycobacterial ınfections in cystic Fibrosis. clin chest Med. 2016;37(1):83-96.

    • Cystic Fibrosis Foundation Patient Registry Annual Data Report,2019.

    • Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, et al.. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol. (1998) 26:371–9. [PubMed] [Google Scholar].

    • Amin R, Dupuis A, Aaron sD, Ratjen F. The effect of chronic infection with Aspergillus fu migatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2010;137 (01):171-6.

    • Armstrong DS, Grimwood K, Carlin jB, Carzino R, olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in in fants with cystic fibrosis. Pediatr Pulmonol. 1996;21:267-75.

    • Rosenfeld m, Emerson j, Accurso F, Arm strong D, Castile R, Grimwood K, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999;28(5):321-8.

    • Kabra SK, Alok A, Kapil A, Aggarwal G, Kabra m, Lodha R, et al. Can throat swab after phys iotherapy replace sputum for identification of microbial pathogens in children with cystic fibrosis? ındian j Pediatr. 2004;71(1):21-3.

    • Suri R, marshall Lj, Wallis C, metcalfe C, Shute jK, Bush A. Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol. 2003;35:309-13.

    • Ho SA, Ball R, morrison Lj, Brownlee KG, Conway SP. Clinical value of obtaining spu tum and cough swab samples following in haled hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol. 2004;38:82-7.

    • Ferkol T, Rosenfeld m, milla CE. Cystic fibrosis pulmonary exacerbations. j Pediatr. 2006;148:259-64.

    • Goss CH, Burns jL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007;62:360-7.

    • Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curropin Pulm med. 2011;17:442-7.

    • Dakin C, Henry RL, Field P, morton j. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol. 2001;31(6):436-42.

    • Rosenfeld m, Emerson j, Williams-Warren j, Pepe m, Smith A, montgomery AB et al. Defin ing a pulmonary exacerbation in cystic fibrosis. j Pediatr. 2001;139(3):359-65.

    • Fuchs HJ, Borowitz DS, christiansen DH, Morris EM, Nash Ml, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-42.

    • Bilton D, canny G, conway S, Dumcius S, Hjelte l, Proesmans M, et al. Pulmonary ex acerbation: towards a definition for use in clinical trials. Report from the EurocarecF Working Group on outcome parameters in clinical trials. J cyst Fibros. 2011;10(Suppl 2): 79-81.

    • Emerson j, Rosenfield m, mcNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91- 100.

    • Britto m, Kotagal U, Hornung R, Atherton H, Tsevat j, Wilmott R. ımpact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121: 64-72.

    • Dobbin Cj, Bartlett D, melehan K, Grunstein RR, Bye PT. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am j Respir Crit Care med. 2005;172:99-104.

    • Flume PA, mogayzel Pj jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn Rj,et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am j Respir Crit Care med. 2009;180(9):802-8.

    • Castellani C, Duff AjA, Bell SC, Heijerman HGm, munck A, Ratjen F et al. ECFS best practice guidelines: the 2018 revision. j Cyst Fibros. 2018;17(2):153-78.

    • johnson C, Butler Sm, Konstan mW, morgan W, Wohl mE. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest. 2003;123:20-7.

    • Sanders DB, Bittner Rc, Rosenfeld M, Hoff man lR, Redding GJ, Goss cH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir crit care Med. 2010;182(5):627-32.

    • https://www.kistikfibrozisturkiye.org/wp-content/uploads/2020/01/Hekim-KF-kitapcik.

    • West NE, Beckett VV, jain R, Sanders DB, Nick jA, Heltshe SL et al. SToP investigators. Standardized Treatment of Pulmonary Exac erbations (SToP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. j Cyst Fibros. 2017;16(5):600-6.

    • Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, et al; SToP Study Group. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (SToP2): A trial to compare intravenous antibiotic treatment du rations in CF. Contemp Clin Trials. 2018;64:35- 40.

    • Hannah Wallace, & Carole Wingett.Saji Alexander. Clinical Guidelines: Care of Children with Cystic Fibrosis Royal Brompton Hospital. 8. bs. 2020

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!